Factor H-Dependent Alternative Pathway Inhibition Mediated by Porin B Contributes to Virulence of Neisseria meningitidis

Lisa A. Lewis
University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs
Part of the Bacteriology Commons, and the Immunology and Infectious Disease Commons

Repository Citation

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Factor H-Dependent Alternative Pathway Inhibition Mediated by Porin B Contributes to Virulence of Neisseria meningitidis

RESEARCH ARTICLE

Factor H-Dependent Alternative Pathway Inhibition Mediated by Porin B Contributes to Virulence of Neisseria meningitidis

Lisa A. Lewis,a David M. Vu,b Shreekant Vasudheva, Jutamas Shaughnessya, Dan M. Granoff,b Sanjay Ram,a

Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USAa; Center for Immunobiology and Vaccine Development, Children’s Hospital Oakland Research Institute, Oakland, California, USAb

ABSTRACT The identification of “factor H binding protein (fHbp)-null” invasive meningococcal isolates and the realization that widespread use of fHbp-based vaccines could herald selection of such strains prompted us to characterize novel mechanisms of alternative pathway (AP) inhibition on meningococci. Of seven strains engineered to lack four known AP-inhibiting molecules, capsular polysaccharide, lipooligosaccharide sialic acid, fHbp, and neisserial surface protein A (quadruple mutants), four strains inhibited human AP-mediated C3 deposition. All four expressed the porin B2 (PorB2) molecule, and three strains belonged to the hypervirulent ST-11 lineage. Consistent with reduced C3 deposition, the rate of C3a generation by a PorB2 isolate was lower than that by a PorB3 strain. Allelic replacement of PorB3 with PorB2, in both encapsulated and unencapsulated strains, confirmed the role of PorB2 in AP inhibition. Expression of PorB2 increased resistance to complement-dependent killing relative to that seen in an isogenic PorB3-expressing strain. Adult rabbit and mouse APs were unimpeded on all mutants, and human fH inhibited nonhuman C3 deposition on PorB2-expressing strains, which provided functional evidence for human fH-dependent AP regulation by PorB2. Low-affinity binding of full-length human fH to quadruple mutants expressing PorB2 was demonstrated. fH-like protein 1 (FHL-1; contains fH domains 1 through 7) and fH domains 6 and 7 fused to IgG Fc bound to one PorB2-expressing quadruple mutant, which suggested that fH domains 6 and 7 may interact with PorB2. These results associate PorB2 expression with serum resistance and presage the appearance of fHbp-null and hypervirulent ST-11 isolates that may evade killing by fHbp-based vaccines.

IMPORTANCE The widespread use of antimeningococcal vaccines based on factor H (fH) binding protein (fHbp) is imminent. Meningococci that lack fHbp were recently isolated from persons with invasive disease, and these fHbp-null strains could spawn vaccine failure. Our report provides a molecular basis for an explanation of how fHbp-null strains may evade the host immune system. Meningococci possess several mechanisms to subvert killing by the alternative pathway (AP) of complement, including production of the fHbp and NspA fH binding proteins. Here we show that a meningococcal protein called porin B2 (PorB2) contributes to inhibition of the AP on the bacterial surface. A majority of the “fHbp-null” isolates identified, as well as all members of a “hypervirulent” lineage (called ST-11), express PorB2. Our findings highlight the potential for the emergence of fHbp-negative strains that are able to regulate the AP and may be associated with fHbp vaccine failure.

Neisseria meningitidis is an important cause of bacterial meningitis and sepsis worldwide. The complement system is an important component of innate immune defenses against this pathogen. Individuals deficient in terminal complement components or in components of the alternative pathway (AP) are at an increased risk of meningococcal disease (1). A key feature of the AP of complement is a positive-feedback loop that amplifies C3 deposition on microbial surfaces (2). The AP also plays an important role in maximizing the killing activity elicited by select antimeningococcal antibodies (Abs) (3). Under physiological conditions, factor H (fH) plays a major role in limiting unwanted activation of the AP (4). fH acts as a cofactor for the factor I-mediated cleavage of C3b to inactive C3b (iC3b) and also serves to limit C3 activation by irreversibly dissociating the AP C3 convertase (C3b, Bb). Microorganisms can hijack host fH and use this molecule to protect themselves from immune attack by downregulating deposition of C3b and inactivating C3b that is deposited.

The meningococcus possesses several distinct and often redundant mechanisms to limit AP activation. Meningococci directly bind human fH through two surface molecules, fH binding protein (fHbp) (5) and neisserial surface protein A (NspA) (6); both serve to limit C3 deposition and enhance resistance of the organism to complement-dependent killing. In addition, sialylation of meningococcal lacto-N-neotetraose (LNT) lipooligosaccharide (LOS) regulates the AP by enhancing the interactions of the
C-terminal domains of fH with surface-bound C3 fragments (7) and the group B and group C capsular polysaccharides limit AP-mediated deposition of C3 (8, 9).

Based on observations that binding of fH to meningococci was human specific (10), we developed a human fH transgenic (Tg) rat which enhanced the ability of H44/76 to cause bacteremia (bacteremia was observed after challenge with $5 \times 10^2$ CFU) (11). Rather unexpectedly, deleting both known fH ligands, fHbp, and NspA, did not diminish the ability of H44/76 to cause bacteremia in human fH Tg infant rats (11); this result suggested the existence of an additional human fH-dependent mechanism(s) for complement evasion. LOS sialylation was identified as one such mechanism (7, 11).

Recent work by Lucidarme et al. (12) identified meningococcal isolates that lacked fHbp expression that had been collected from patients with invasive disease, which demonstrated that in select strains, fHbp was dispensable for virulence in humans. These findings imply that certain meningococcal strains possess novel means of inhibiting complement activation in the absence of fHbp. This observation is particularly important given that fHbp-based vaccines are on the verge of clinical use.

The aim of the present study was to identify novel mechanisms meningococci use to regulate the AP that could contribute to the virulence of this pathogen in the absence of fHbp. These mechanisms could contribute to the ability of fHbp-negative meningococci to maintain virulence and escape killing by fHbp-containing vaccines.

RESULTS

Meningococcal PorB2 strains regulate the human AP. In order to study AP regulation in the absence of factors known to modulate C3 deposition on meningococci, we created mutants that lacked expression of capsular polysaccharide, LOS sialic acid, fHbp, and NspA. Strains harboring these four mutations simultaneously are referred to here as “quadruple mutants.” Quadruple mutants, derived from 7 diverse strains of N. meningitidis (see Table S1 in the supplemental material), were screened for deposition of human C3 following incubation with normal human serum-MgCl2-EGTA (NHS-Mg/EGTA) (20% [vol/vol]); Mg/EGTA blocked classical and lectin pathway activation and allowed assessment of AP activation only (Fig. 1). Significantly lower C3 deposition was seen on quadruple mutants generated from four strains that expressed the PorB2 molecule than on mutants generated from strains that expressed PorB3 (Fig. 1A and B). Similar results were seen with C2-depleted serum (only AP intact; classical and lectin pathways blocked) and with sera from two additional donors (data not shown).

To ensure that serum factors other than AP components did not contribute significantly to the differential C3 deposition on the meningococcal mutants, we examined C3 deposition on the strains using purified C3, factor B, factor D, and fH (Fig. 1C). Again, each of the four PorB2-expressing quadruple mutants showed significantly ($P < 0.01$) lower C3 deposition than each of the three PorB3 isolates. These data indicate that despite loss of capsule, LOS sialic acid, fHbp, and NspA, select PorB2 strains effectively regulated the human AP.

Decreased C3 deposition in PorB2 strains is associated with slower C3 activation. Decreased C3 deposition could result from reduced targets for covalent binding of C3 (i.e., fewer electron-donating –OH groups) or decreased activation of C3 on the bacterial surface (i.e., because of increased fH binding) or a combination of these events. The quantitative differences seen by flow cytometry (Fig. 1) were confirmed by Western blotting (see Fig. S1 in the supplemental material), which revealed both LOS and Opa as major targets for iC3b across all isolates, as has been previously described for Neisseria (13). LOS structure can modulate complement activation on neisseriae (7, 8, 14). All strains expressed an ~4.5-kDa LOS species; NZ98/254 showed an additional 3.6-kDa LOS species (data not shown). Thus, there was no obvious correlation between the LOS migration pattern and the amount of C3 deposited.

Activation of C3 is accompanied by release of the C3a fragment, and measurement of the rate of C3a generation reflects C3 activation kinetics. Based on previously published data that measured the rates of complement activation (9), we focused on C3a production during the first 15 min of incubation. Quadruple mutants of 4243 (PorB2) and H44/76 (PorB3) were chosen as examples of low- and high-level C3 binders, respectively. As shown in Fig. 1D, the reaction mixture containing the 4243 mutant generated C3 at a rate lower than that seen with H44/76. The total amounts of C3a in the reaction mixture reached similar levels across strains at time points at or beyond 20 min, likely because C3 convertases in the fluid phase contribute to overall complement activation (9). These data suggest that lower C3 deposition on strain 4243 occurs at least in part because of a lower rate of C3 activation.

Human fH regulates the AP of nonhuman complement on PorB2-expressing quadruple mutants. Binding of fH to the known meningococcal ligands for fH, fHbp, and NspA is human specific (6, 10). To determine if regulation of the AP by PorB2-bearing strains was also specific to humans, we measured deposition of rabbit and mouse C3 using adult sera. PorB2 did not regulate the AP of these adult animals, and similar amounts of C3 were deposited on all quadruple mutants (Fig. 2, black bars). The addition of purified human fH to these nonhuman sera resulted in significantly greater downregulation of the AP on PorB2 strains relative to that seen with PorB3 isolates (Fig. 2, gray bars). Fluorescence-activated cell sorter (FACS) tracings of a representative experiment are shown in Fig. S2 in the supplemental material. These data provide strong evidence for human fH-dependent regulation of the AP by PorB2-bearing strains compared to PorB3-bearing strains.

Confirmation of the role of PorB2 in regulating the human AP. PorB is a major outer membrane protein that contributes to the fitness of a strain (15), and its deletion could have pleiotropic effects with respect to bacterial growth in addition to any interactions with the complement system. To avoid these concerns, we created allelic exchanges of the entire porB2 and porB3 sequences in a homologous background and compared C3 deposits in these isogenic strains that differed only in PorB types. Two sets of mutants were created; the first set lacked fHbp, NspA, capsule, and LOS sialic acid (H44/76 “quadruple”-PorB3 and H44/76 “quadruple”-PorB2), while the second set lacked fHbp and NspA but elaborated capsule and sialylated LOS (H44/76 fHbp nspA-PorB3 and H44/76 fHbp nspA-PorB2).

H44/76 that expressed PorB2 showed greater downregulation of C3 deposition than H44/76 that expressed its own PorB3 molecule (Fig. 3). The effect was most pronounced in the absence of capsule (Fig. 3A; “Cap=”) but was also observed in the encapsulated (Fig. 3C; “Cap+”) background (quantitative comparisons...
are shown in Fig. 3B and D, respectively). These data provide strong evidence for a role for PorB2 in regulating the human AP on meningococci.

C3 deposition on PorB2-expressing strains displays a bimodal distribution (Fig. 1B and 3A; see also Fig. S3 in the supplemental material). These data suggest that there are two populations that differentially regulate the AP. PorB2 expression was normally distributed (unimodal) and did not correlate with variation in C3 deposition. Regions of low, intermediate, and high PorB2 expression from within the normally distributed PorB2-positive population all revealed bimodal C3 deposition (Fig. S3). Thus, molecules other than PorB2 could contribute to the observed heterogeneity in C3 deposition.

Binding of fH, fH/Fc fusion proteins, and fH-like protein 1 (FHL-1) to meningococci lacking fHbp and NspA. Having provided evidence for human fH-dependent downregulation of the AP by PorB2-bearing strains, we compared the abilities of H44/76 “quadruple”-PorB3 and H44/76 “quadruple”-PorB2 to bind to human fH. Using standard FACS analysis (Fig. 4A [see also Fig. S4A in the supplemental material]; labeled “no cross-linker”) and Western blot (data not shown) methods, we did not detect binding of full-length human fH (100 μg/ml) to either strain. Similar negative results were obtained with the 7 quadruple mutants that express either PorB2 (C2120, W171, 4243, and 2996) or PorB3 (A2594, H44/76, and NZ98/254) (Fig. 4B [see also Fig. S4B]; labeled “no cross-linker”). To enhance detection of low-affinity interactions between fH and PorB, we added paraformaldehyde to cross-link bound fH to the bacterial surface prior to washing and then detected bound fH by FACS analysis (the terms “low” and “high” affinity are henceforth used to refer to low-level fH binding that can be detected only with a cross-linker and high-level fH binding that can be detected without a cross-linker). In the presence of the cross-linker, the quadruple mutant of H44/76 expressing PorB2 bound greater amounts of fH than the isogenic H44/76 bearing PorB3 (Fig. 4A [see also Fig. S4A]; labeled “paraformaldehyde cross-linker”). In other experiments, quadruple
murine IgG2a Fc (fH67/Fc and fH18-20/Fc) to H44/76 “quadruple”-PorB3 and H44/76 “quadruple”-PorB2 demonstrated that fH67/Fc specifically bound to H44/76 expressing PorB2,243 (Fig. 4C; gray-shaded histogram) but not to H44/76 expressing the homologous PorB3 molecule (Fig. 4C; red histogram). The quadruple mutant of 4243, but not other strains (data not shown), also bound fH67/Fc (Fig. 4C; green histogram). Binding of fH67/Fc to H44/76 “quadruple”-PorB2 (Fig. 4C; gray histogram) was decreased relative to binding of the quadruple mutant of 4243 (Fig. 4C; green histogram), suggesting that the strain background may be important for this interaction. fH18-20/Fc did not bind to any quadruple mutant tested (data not shown).

*N. meningitidis* can also bind to fH-like protein 1 (FHL-1), a molecule that contains the first seven N-terminal domains of fH (18) and regulates the AP. Consistent with binding of fH67/Fc, the quadruple mutant of 4243, but not other strains (data not shown), bound purified FHL-1 (Fig. 4D). Binding of FHL-1 and fH67/Fc to wild-type H44/76 expressing both fHbp and NspA is shown as a positive control. All isolates expressed similar amounts of PorB as assessed using Coomassie-stained gels, which suggested that differences in PorB expression did not account for differences in AP regulation or binding of FHL-1 or fH67/Fc (data not shown).

To better understand the differences in binding of FHL-1 and fH67/Fc among the PorB2 isolates, the translated amino acid sequences were aligned (see Fig. S5 in the supplemental material). The only difference between PorB2 of 4243, which bound FHL-1 and fH67/Fc with high affinity, and the PorB2 molecules of W171 and C2120, which did not, was the absence of a 3-amino-acid stretch in predicted surface-loop 7 in the latter 2 strains (VKD deleted in W171 and NGV deleted in C2120). The 4243 loop 7 sequence alone likely was not sufficient to mediate high-affinity binding of fH67/Fc to PorB2, because the amino acid sequence of loop 7 of PorB2 2996 was identical to that of 4243; yet 2996 did not bind detectable amounts of fH67/Fc in the absence of cross-linker. Outside loop 7, the 2996 PorB2 was the most divergent from 4243, with 12 amino acid differences (see Fig. S5). The amino acid sequence of PorB2 4243 was identical to that of a group C strain called FAM18; a quadruple mutant of FAM18 also bound fH67/Fc and regulated the human AP (see Fig. S6 in the supplemental material). This observation further supports the idea of a role of PorB2 in regulating the AP.

All PorB2 strains tested regulated the AP (Fig. 1), and in all cases this regulation was dependent on the presence of human fH (Fig. 2). All PorB2-expressing strains bound full-length fH when a cross-linker was used to detect low-affinity binding, and 4243 bound FHL-1 with high affinity in the absence of cross-linker. Collectively, these data suggest that AP regulation by human fH involves low-affinity PorB2-fH interactions.

**Expression of PorB2 enhances serum resistance.** To determine the relative roles of PorB2 and PorB3 in serum resistance, we compared the abilities of H44/76 *fHbp nspA* and PorB3 and H44/76 *fHbp nspA* and PorB2 to resist killing by human serum. Strains lacking *fHbp* and *NspA* were used to avoid the confounding effects of fH binding to these ligands. Serum was absorbed against a mixture of H44/76 *fHbp nspA*-PorB3 and H44/76 *fHbp nspA*-PorB2 to remove strain-specific antibodies. Absorbed serum (20%) alone did not kill either strain (Fig. 5). Expression of PorB2 by H44/76 *fHbp nspA* resulted in greater resistance to complement-dependent killing mediated by anti-group B capsule IgG antibody SEAM 12 (19).
than expression of PorB3 (Fig. 5). Absorbed serum treated with Mg/EGTA to selectively activate the AP did not initiate killing of either strain in the presence or absence of SEAM 12 (**100% survival in both instances). As previously reported for other antimeningococcal Abs (3), the AP was required for maximal killing; blocking the AP with an anti-factor Bb monoclonal antibody (MAb) decreased killing of H44/76 fHbp nspA-PorB3 and H44/76 fHbp nspA-PorB2; “Cap−”). Bacteria were incubated with NHS-Mg/EGTA (20% [vol/vol]), and C3 deposited on the bacterial surface was measured by FACS analysis. (A and C) Representative histogram tracings of C3 deposition on the unencapsulated (Cap−) and encapsulated (Cap+) strains. Bacteria incubated with heat-inactivated serum served as negative controls (dashed lines). (B and D) Quantitative representation (percentage of positive events on the y axis; mean [SEM] of the results of three independent experiments) of C3 deposition on the Cap− and Cap+ isogenic PorB mutants, respectively. The percentage of positive events relative to control organisms incubated with heat-inactivated serum (gated to yield 5% of positive events in the negative-control sample as shown in Fig. 1B [+ve]) is represented on the y axis. Wild-type parent strains H44/76 and 4243 are shown as comparators. Note the different y-axis scales in panels B and D. ***, P < 0.001; **, P < 0.01.

**DISCUSSION**

PorB, one of the most abundant proteins in the neisserial outer membrane, is an integral membrane protein organized as a β barrel with 16 transmembrane domains and 8 predicted surface loops (20). PorB functions as a porin, allowing the passage of small molecules across the outer membrane, and has also been implicated in virulence. Gonococcal PorB has been shown to play a key role in regulation of both the AP and classical pathways of complement by virtue of its ability to bind to fH and C4BP, respectively (21, 22). Meningococcal PorB is divided into two classes, PorB2 and PorB3, which are mutually exclusive and are expressed...
from alternate alleles (porB2 and porB3) at the porB locus. PorB3 of N. meningitidis serves as a ligand for Toll-like receptor 2 (TLR2) and activates cells through a TLR2/TLR1-dependent pathway (23).

The goal of our study was to examine AP regulation in strains that did not rely on fHbp or NspA expression. We have identified a novel role for meningococcal PorB2 in regulation of the AP of complement. Concurrent with our studies, Lucidarme and colleagues described 29 invasive meningococcal isolates that lacked fHbp expression (12). Of these strains, nine belonged to the “hypervirulent” ST-11 lineage. It is noteworthy that strains that belong to the hypervirulent ST-11 clonal complex express PorB2. In an ongoing analysis of select strains reported by Lucidarme et al., three of four non-ST-11 isolates also expressed PorB2 (24). Although anti-capsule MAb SEAM 12 could overcome AP regulation and initiate in vitro killing of meningococci, maximal killing required the AP. Further, our studies demonstrated that expression of PorB2, relative to PorB3, enhanced the ability of H44/76 fHbp nspA to evade complement-mediated killing. Similarly, expression of PorB2 may render strains more resistant to complement-dependent killing in humans. The ability to regulate complement and cause invasive disease in the absence of fHbp expression may offer these strains a distinct advantage when faced with immune pressure by anti-fHbp antibodies, which is a likely occurrence with clinical use of fHbp-containing vaccines (25, 26).

N. meningitidis contains an array of antigenic determinants that serve as ligands for innate immune receptors. PorB3 serves as a ligand for Toll-like receptor 2 (TLR2). PorB2 is a novel ligand for complement receptor 1 (CR1). The goal of our study was to examine AP regulation in strains that did not rely on fHbp or NspA expression. We have identified a novel role for meningococcal PorB2 in regulation of the AP of complement. Concurrent with our studies, Lucidarme and colleagues described 29 invasive meningococcal isolates that lacked fHbp expression (12). Of these strains, nine belonged to the “hypervirulent” ST-11 lineage. It is noteworthy that strains that belong to the hypervirulent ST-11 clonal complex express PorB2. In an ongoing analysis of select strains reported by Lucidarme et al., three of four non-ST-11 isolates also expressed PorB2 (24). Although anti-capsule MAb SEAM 12 could overcome AP regulation and initiate in vitro killing of meningococci, maximal killing required the AP. Further, our studies demonstrated that expression of PorB2, relative to PorB3, enhanced the ability of H44/76 fHbp nspA to evade complement-mediated killing. Similarly, expression of PorB2 may render strains more resistant to complement-dependent killing in humans. The ability to regulate complement and cause invasive disease in the absence of fHbp expression may offer these strains a distinct advantage when faced with immune pressure by anti-fHbp antibodies, which is a likely occurrence with clinical use of fHbp-containing vaccines (25, 26).

Natural disruption of PorA (27, 28) and NadA (IS1301) (29), which are both components of the proposed vaccine, has also been reported in the ET-15 subset of the ST-11 complex.
We have provided considerable functional evidence for human fH-dependent inhibition of the AP by PorB2. A novel finding of this study was the low affinity of the interaction between full-length fH and PorB2 on intact bacteria. fH is present in serum at concentrations of 200 to 500 μg/ml. The low affinity of the interaction between full-length fH and PorB2 may result from structural constraints in intact fH that reduce its affinity for intact bacteria. A more detailed understanding of the regions of PorB that are required for functional interactions with fH may aid in the prediction of specific PorB molecules that may be involved in complement evasion.

This report sheds light on an important immune evasion function mediated by meningococcal PorB. In light of the functional role of PorB in complement evasion, it is conceivable that implementation of fHbp-containing vaccines could shift from relying on demonstration of high-affinity binding to examining more functional readouts of complement activation.

MATERIALS AND METHODS

Ethics statement. This study was approved by the Committee for the Protection of Human Subjects in Research at the University of Massachusetts Medical School. All subjects who donated blood for this study provided written informed consent.

Bacterial strains and culture conditions. Characteristics of the wild-type strains used to derive the mutants used in this study are listed in Table S1 in the supplemental material. N. meningitidis bacteria were routinely grown on chocolate agar plates supplemented with IsoVitalex equivalent at 37°C in an atmosphere with 5% CO2. GC plates supplemented with IsoVitalex equivalent were used for antibiotic selection. Escherichia coli bacteria (Invitrogen, Carlsbad, CA) were cultured in Luria-Bertani broth or agar with antibiotics as needed. Antibiotics were used at the concentrations indicated in Table S2 in the supplemental material.

Strains were rendered unencapsulated by interruption of mynB (group A) or siaD (group B, C, or W135) (6, 34). Insertional inactivation of lst (ls:t:kan) abrogated LOS sialylation of group B, C, and W135 isolates as previously described (6, 34). Group A strains do not sialylate their LOS unless cytidinemonophospho-N-acetylneuraminic acid (CMP-NANA) is added to growth media. fHbp and Nspa expression was abrogated (fHbp::erm [5] and nspa::spc [6], respectively) as previously described.

PorB deletion mutants of H44/76 fHbp nspa were constructed using a plasmid that contained (5' to 3') an 800-bp region 5' to PorB2::kan (amplified with porMC58up_F_Apal and porMC58up_R_SacI; see Table S3 in the supplemental material), the aphA3 kanamycin resistance determinant, and a 1,100-bp region 3' to PorB3 (amplified with porMC58Down_F_SpeI and porMC58Down_R_SacI; see Table S3). Meningococcal strains were transformed as previously described.

PorB allelic replacements in H44/76 were made using the H44/76 PorB deletion strain and chromosomal DNA isolated from either 4243 or H44/76 containing the TetM tetracycline resistance cassette downstream of porB2 or porB3, respectively. This ensured complete replacement of porB and eliminated the potential formation of hybrid PorB2/PorB3 molecules. TetM was inserted downstream of porB in each strain using plasmids that contained either porB3 (amplified with MC88::porB3_SacI and MC88::porB3_F_Apal; see Table S3 in the supplemental material) or porB2 (amplified with FAM18::porB2_F_Apal and Nlo::porB2_SacI; see Table S3) followed by TetM and the 1,100-bp region 3' to porB3 described above. Transformants were selected for tetracycline resistance and checked for sensitivity to kanamycin. All clones were verified by DNA sequencing.

Sera. Normal human serum (NHS) was obtained from healthy adult volunteers, divided into aliquots, and stored (as individual sera) at 80°C till used. To inactivate selectively the classical and lectin complement pathways, NHS was treated with heat-inactivated (HI) sera and NHS without added SEAM 12 (0 μg/ml) served as controls. Percent survival relative to time 0 is plotted on the y axis. Each bar represents the SEM of the results of three independent observations.

** P < 0.01; ****, P < 0.0001 (2-way ANOVA).

FIG 5 PorB2 expression enhances serum resistance. Data represent percent survival of isogenic H44/76 fHbp nspa expressing either PorB2::kan (PorB2; open bar) or PorB3::kan (PorB3; gray bar) in 20% absorbed serum that contained anti-group B capsule antibody, SEAM 12, at the concentrations indicated. Heat-inactivated (HI) sera and NHS without added SEAM 12 (0 μg/ml) served as controls. Percent survival relative to time 0 is plotted on the y axis. Each bar represents the SEM of the results of three independent observations.

** P < 0.01; ****, P < 0.0001 (2-way ANOVA).

We were able to demonstrate high-affinity binding of FHL-1 and fH67/Fc to strains expressing PorB2. These findings were confirmed in strain FM18, which expresses a PorB2 with an amino acid sequence identical to that of 4243. High-affinity binding of these “fragments” of fH, but not the full-length fH, to strains expressing PorB2 may result from structural constraints in intact fH that reduce its affinity for intact bacteria. A more detailed understanding of the regions of PorB that are required for functional interactions with fH may aid in the prediction of specific PorB molecules that may be involved in complement evasion.

This report sheds light on an important immune evasion function mediated by meningococcal PorB. In light of the functional role of PorB in complement evasion, it is conceivable that implementation of fHbp-containing vaccines could shift from relying on demonstration of high-affinity binding to examining more functional readouts of complement activation.
pathways and isolate the AP as the only active pathway. MgCl₂ and EGTA (10 mM each) were added to NHS (NHS-Mg/EGTA).

Absorbed sera, in which antibodies specific to H44/76 fHbp nspA PorB3 and H44/76 fHbp nspA PorB2 were removed, were prepared as follows. EDTA (10 mM) was added to fresh NHS, and the sera were dialyzed against phosphate-buffered saline (PBS)–1 mM EDTA for 4 h at 4°C using a 10-kDa molecular mass cutoff. Meningococcal strains were subjected to passage on overnight plates and added onto fresh chocolate agar plates and grown for 5 h. Bacteria were harvested and washed once with PBS–1 mM EDTA. Dialyzed serum was absorbed twice with bacteria (1-mL serum with a mixture of 100 µL of packed cells from each of the 2 mutant strains) processed end over end for 30 min at 4°C. The serum was filtered (0.22-µm- pore-size filter), divided into aliquots, and stored at -80°C. Ca²⁺ and Mg²⁺ (2 mM each) were added prior to use. Similar amounts of fH were detected (MAb 90X) in NHS and absorbed sera spot-blotted experiments confirmed the specificity and cross-reactivity of anti-guinea pig C3 FITC with rabbit C3. Binding is represented either as a percentage of positive events (relative to a negative control that was gated to yield 5% of positive events) when histogram tracings showed a non-Gaussian distribution or as median fluorescence of the entire bacterial population when all samples yielded normally distributed histograms.

**C3 generation assay.** Bacteria (~2 × 10⁸) were incubated with 20% NHS-Mg/EGTA in an initial reaction volume of 200 µL. Samples (10 µL) were collected at specified intervals between 0 min and 15 min and diluted immediately in 90 µL PBS–50 mM EDTA. C3a in the reaction mixture was measured using a MicroVue C3a Plus ELISA kit (Quidel) according to the manufacturer’s instructions.

**Statistical analyses.** Statistical comparisons across multiple groups were carried out using 1-way analysis of variance (ANOVA) with Tukey’s posttest for pairwise comparisons. Differences in C3a generation and bacterial survival between strains were measured using 2-way ANOVA with Bonferroni’s posttest. All probability values, with the exception of the 1-way ANOVA, are two tailed.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.00339-13/-/DCSupplemental.

**REFERENCES**

bonds to factor H and enhances meningoococcal resistance to complement. PLoS Pathog. 6:e1001027.


